Integrating Scientific Innovation and Health Equity

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. These advances have transformed the outlook for people affected by HIV worldwide. In parallel, Gilead’s focus on catalytic collaborations at the global, national and local levels have helped to address the unmet needs of a wide range of individuals and communities.
Jared Baeten is a physician, epidemiologist and head of R&D at Gilead Sciences who has spent decades working in partnership with collaborators around the world to help overcome the HIV epidemic. In this episode he discusses:

The current landscape of HIV research

Optionality and choice in HIV treatment and care

Beyond the lab: education, access and barriers to care

Achieving the collective vision of ending the HIV epidemic

This podcast was created by our partner Gilead Sciences and produced by New Scientist CoLab.
Hosted on Acast. See acast.com/privacy for more information.
Learn more about your ad choices. Visit megaphone.fm/adchoices